Apogee Therapeutics, Inc. (Nasdaq:APGE)
Health Care/Life Sciences • Biotechnology
CIK 1974640
Company
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.
Address
221 Crescent Street
Building 17, Suite 102b
Waltham, Massachusetts 02453
221 Crescent Street
Building 17, Suite 102b
Waltham, Massachusetts 02453
Employees
None
None
Stock Info
Key Executives
Board Of Directors
Chairman Mark C Mckenna MBA |
Chief Executive Officer & Director Michael Henderson MD |
Director William A Jones Jr., MBA |
Director Andrew Gottesdiener MBA |
Director Tomas Kiselak |
Director Nimish P Shah MBA |
Director Peter Harwin |
Independent Director Jennifer Fox |
SEC filings
Date | Form | Event |
---|---|---|
16 Dec, 2024 | 4 | |
13 Dec, 2024 | 4 | |
11 Dec, 2024 | 144 | |
11 Dec, 2024 | 4 | |
11 Dec, 2024 | 4 | |
11 Dec, 2024 | 4 | |
10 Dec, 2024 | 8-K | |
6 Dec, 2024 | 4 | |
6 Dec, 2024 | 4 | |
4 Dec, 2024 | 144 | |
2 Dec, 2024 | 8-K | |
14 Nov, 2024 | SC 13G/A | |
14 Nov, 2024 | SC 13G | |
14 Nov, 2024 | SC 13G/A | |
12 Nov, 2024 | 8-K | |
12 Nov, 2024 | SC 13G/A | |
12 Nov, 2024 | 10-Q | |
8 Nov, 2024 | 4 | |
8 Nov, 2024 | SC 13G | |
8 Nov, 2024 | 4 | |
6 Nov, 2024 | 144 | |
4 Nov, 2024 | SC 13G/A | |
24 Oct, 2024 | 8-K | |
22 Oct, 2024 | SC 13G | |
4 Oct, 2024 | 4 | |
4 Oct, 2024 | SC 13G | |
4 Oct, 2024 | 4 | |
2 Oct, 2024 | 144 | |
2 Oct, 2024 | 144 | |
6 Sep, 2024 | 4 | |
6 Sep, 2024 | 4 | |
4 Sep, 2024 | 144 | |
23 Aug, 2024 | 144 | |
23 Aug, 2024 | 4 | |
19 Aug, 2024 | 8-K | |
12 Aug, 2024 | 10-Q | |
12 Aug, 2024 | 8-K | |
12 Aug, 2024 | S-8 | |
12 Aug, 2024 | S-3ASR | |
9 Aug, 2024 | 4 | |
9 Aug, 2024 | 4 | |
7 Aug, 2024 | 144 | |
5 Jul, 2024 | 4 | |
5 Jul, 2024 | 4 | |
5 Jul, 2024 | 144 | |
3 Jul, 2024 | 144 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 8-K | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
30 May, 2024 | 4 | |
30 May, 2024 | 3 | |
28 May, 2024 | 8-K | |
28 May, 2024 | DEFA14A | |
15 May, 2024 | 8-K | |
13 May, 2024 | 10-Q | |
13 May, 2024 | 8-K | |
13 May, 2024 | S-8 | |
24 Apr, 2024 | DEFA14A | |
24 Apr, 2024 | DEF 14A | |
24 Apr, 2024 | ARS | |
1 Apr, 2024 | SC 13D/A | |
1 Apr, 2024 | 4 | |
25 Mar, 2024 | 8-K | |
11 Mar, 2024 | 424B4 | |
7 Mar, 2024 | S-1MEF | |
7 Mar, 2024 | EFFECT | |
5 Mar, 2024 | CORRESP | |
5 Mar, 2024 | 10-K | |
5 Mar, 2024 | S-1 | |
5 Mar, 2024 | 8-K | |
5 Mar, 2024 | 8-K | |
5 Mar, 2024 | CORRESP | |
29 Feb, 2024 | UPLOAD | |
14 Feb, 2024 | SC 13G | |
14 Feb, 2024 | SC 13G/A | |
9 Feb, 2024 | DRS | |
9 Feb, 2024 | SC 13G/A | |
31 Jan, 2024 | SC 13D/A | |
31 Jan, 2024 | 4 | |
20 Dec, 2023 | 4 | |
20 Dec, 2023 | 4 | |
20 Dec, 2023 | 4 | |
13 Nov, 2023 | 10-Q | |
13 Nov, 2023 | 8-K | |
3 Nov, 2023 | SC 13G | |
28 Aug, 2023 | 8-K | |
28 Aug, 2023 | S-8 | |
28 Aug, 2023 | 10-Q | |
21 Aug, 2023 | 8-K | |
21 Aug, 2023 | 4 | |
21 Aug, 2023 | 3 | |
10 Aug, 2023 | SC 13G | |
7 Aug, 2023 | 8-K | |
28 Jul, 2023 | SC 13D | |
25 Jul, 2023 | SEC STAFF | |
24 Jul, 2023 | SC 13G | |
21 Jul, 2023 | SC 13D | |
17 Jul, 2023 | 3/A | |
17 Jul, 2023 | 4 | |
17 Jul, 2023 | 4 | |
17 Jul, 2023 | 424B4 | IPO completed |
17 Jul, 2023 | 4 | |
17 Jul, 2023 | 3/A | |
17 Jul, 2023 | 3/A | |
17 Jul, 2023 | 3/A | |
17 Jul, 2023 | 3/A | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | S-1MEF | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
12 Jul, 2023 | CERT | |
11 Jul, 2023 | CORRESP | |
11 Jul, 2023 | CORRESP | |
10 Jul, 2023 | CORRESP | |
10 Jul, 2023 | 8-A12B | |
10 Jul, 2023 | S-1/A | |
3 Jul, 2023 | S-1/A | |
30 Jun, 2023 | UPLOAD | |
22 Jun, 2023 | CORRESP | |
22 Jun, 2023 | S-1 | |
16 Jun, 2023 | UPLOAD | |
12 Jun, 2023 | SEC STAFF | |
5 Jun, 2023 | DRS/A | |
5 Jun, 2023 | DRSLTR | |
2 Jun, 2023 | UPLOAD | |
28 Apr, 2023 | DRS |
Last update:2024-03-06 12:23:29.640029
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.